Anebulo Q3 FY2024 net loss $0.06/shr vs $0.11; pivots to pediatric cannabis antidote

Anebulo Pharmaceuticals, Inc.

2024-Q3 EPS reported -$0.27

Net loss $1.7M ($0.06/shr), narrower than $2.8M ($0.11) a year ago; operating expenses $1.7M (down 41%).
Cash and equivalents $5.1M as of March 31, 2024, down from prior quarter but no near-term capital raise flagged.
Prioritizing IV formulation of selonabant for unintentional cannabis poisoning in children, citing growing medical need.
DEA plans to reclassify marijuana as Schedule III cited as tailwind; FDA discussions support alternative formulation for pediatric use.
Adult ACI treatment remains market opportunity but pediatric path seen as faster to approval; Phase 2 oral study data already completed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Anebulo Pharmaceuticals, Inc. reported three months ended March 31, 2024 results: net income Net loss ... was $1.7 million, or $(0.06) per share, EPS $(0.06) per share.

Period: three months ended March 31, 2024
Net income: Net loss ... was $1.7 million, or $(0.06) per share
EPS: $(0.06) per share
Result: reported results

Exact text from the filing

today announced financial results for the three months ended March 31, 2024

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Anebulo Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-019877

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.